Binds A Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 435/337)
-
Patent number: 6221659Abstract: Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.Type: GrantFiled: January 16, 1998Date of Patent: April 24, 2001Assignee: Corvas Inc.Inventors: Howard R. Soule, Terence K. Brunck
-
Patent number: 6150114Abstract: A method for determining the amount of an antiplatelet compound in a subject being treated with the compound which comprises calculating the ACT number of the subject's blood containing a reagent which immunoreacts with the antiplatelet compound and comparing the figure to a standardized concentration figure. In subjects concurrently being treated with heparin and antiplatelet compounds, the method can be practiced without additional heparin added to the blood sample. The invention also provides reagents which immunoreact with antiplatelet compounds and kits comprising immunoreactive reagents.Type: GrantFiled: May 15, 1997Date of Patent: November 21, 2000Assignee: G. D. Searle & Co.Inventors: Larry P. Feigen, Christopher P. Carron, Neal F. Haas, Debra M. Meyer, Jimmy D. Page, Jodi A. Pegg
-
Patent number: 6043087Abstract: The invention provides a monospecific antibody that is specifically reactive with enzymatically mediated degradation products of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances). The monospecific antibody of the invention is specifically reactive with an epitope defined by an amino acid sequence SEQ ID NO:1. The invention further provides compositions containing a monospecific antibody, optionally detectably labeled, for the performance of fibrinolytic or thrombolytic analyses. The invention further provides continuous cell lines (hybridomas) that produce monospecific antibodies as described.Type: GrantFiled: July 25, 1997Date of Patent: March 28, 2000Assignee: The New York Blood CenterInventors: Alessandra Bini, Bohdan J. Kudryk
-
Patent number: 6025143Abstract: The present invention relates to peptides and polypeptides derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls:X-His-Asn-Pro-Yin which X represents a Gln or Pro-Glu residue and Y represents an OH group or residue of a basic amino acid. The present invention also relates to corresponding polyclonal and monoclonal antibodies as well as corresponding hybridomas. The products of the present invention are useful for therapeutic, diagnosis and detection purposes.Type: GrantFiled: June 7, 1995Date of Patent: February 15, 2000Assignee: Institut PasteurInventors: Isabelle Rosinski-Chupin, Diana Tronik, Francois Rougeon, Nabil Seidah
-
Patent number: 6010903Abstract: Disclosed is a monoclonal antibody which specifically reacts with active human ceruloplasmin as well as a method for diagnosing Wilson's disease using the same. The monoclonal antibody of the present invention specifically reacts with active human ceruloplasmin, it neutralizes the peroxidase activity of the active human ceruloplasmin upon binding thereto, and it does not specifically react with inactive human ceruloplasmin.Type: GrantFiled: April 7, 1995Date of Patent: January 4, 2000Assignee: Idemitsu Kosan Company LimitedInventors: Shuichi Hiyamuta, Keiko Shimizu, Akihiko Kadota
-
Patent number: 5972628Abstract: A qualitative, quantitative, as well as local determination of pyruvatkinase (ATP:pyruvate-2-O-phosphotransferase, EC 2.7.1.40)-isoenzyme typ M2 (Tumor-M2-PK) is possible in blood, plasma, tissue culture, tissue sections as well as in the animal and human organism with the help of antibodies.Corresponding antisera are obtained if highly purified pyruvatekinase-isoenzymes type M2 (Tumor-M2-PK) or fragments of these, are used as immunogen. Preferable are antisera with monoclonal antibodies.These antibodies can be used in ELISA-Test systems for the diagnosis of cancer, to determine the malignancy of cells, to localize a tumor in an organism as well as for the therapy of cancer.Type: GrantFiled: September 9, 1994Date of Patent: October 26, 1999Assignee: ScheBo Tech Medizinisch-Biologische Forschungsgesellschaft m.b.H.Inventors: Erich Eigenbrodt, Manfred Reinacher, Ursula Scheefers-Borchel, Hans Scheefers
-
Patent number: 5972632Abstract: Immunoassays for complement components, complement activation products or, preferably both, can be used to determine an acceptable level of anticomplement activity (AC) in plasma derived biologically active products intended for infusion into a mammal. In one application an ELISA for complement components (CC) such as C1q, C1r or C1s can be used to determine AC in an IgM-enriched immune serum globulin (ISG). In another application, an immunoassay for complement activation products (CAP) is used for a similar determination. In yet a preferred third application, assays for both a CC (such as measuring a decreasing amount of C1r) and a CAP (such as measuring an increasing amount of C4a) are used to assess the relative AC (and safety) of a biologically active, therapeutic preparation.Type: GrantFiled: April 22, 1991Date of Patent: October 26, 1999Assignee: Bayer CorporationInventors: Grace C. Tsay, Neal Cheung
-
Patent number: 5955582Abstract: Methods of preparing a boronate-antigen complex for immunization of animals, a monoclonal antibody specific for the same, an immunoassay method for detection of the complex and a method of calculating the amount of a target glycated protein within the sample useful in the diagnostic monitoring of diabetes are disclosed. An immunoassay kit based on this reagent is also disclosed.Type: GrantFiled: September 26, 1997Date of Patent: September 21, 1999Assignee: Beckman Coulter, Inc.Inventors: Karel Z. Newman, Bruce Odegaard, Godwin Orji Ogbonna, Jane A. Schmidt
-
Patent number: 5916805Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.Type: GrantFiled: June 27, 1997Date of Patent: June 29, 1999Assignee: Ajinomoto Co., Inc.Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
-
Patent number: 5888753Abstract: The invention relates to monoclonal antibodies (MAbs) and fragments thereof which have a specific affinity for the plasmin-antiplasmin complex and which display no affinity or only a very low affinity for the individual components of these complexes, and to antigens which can be defined and/or isolated with the aid of these antibodies or antibody fragments. The antibodies, antibody fragments and antigens can be used as diagnostic aid, active substance or active substance carrier.Type: GrantFiled: May 14, 1992Date of Patent: March 30, 1999Assignee: Behring Diagnostics GmbHInventors: Johann Hock, Hermann Pelzer
-
Patent number: 5877006Abstract: Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.Type: GrantFiled: May 17, 1995Date of Patent: March 2, 1999Assignees: Centocor, Inc., The Research Foundation of State of New YorkInventors: Barry S. Coller, David M. Knight
-
Patent number: 5871737Abstract: The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized germfree animal. The invention also provides methods for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized germfree animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.Type: GrantFiled: March 19, 1998Date of Patent: February 16, 1999Assignee: American Biogenetic Sciences, Inc.Inventors: Paul E. Gargan, Victoria A. Ploplis, Julian R. Pleasants
-
Patent number: 5866689Abstract: Monoclonal antibodies recognizing gp130 protein and binding to the protein to inhibit IL-6 functions completely (that is to the same level as that is the absence of IL-6) when present in enough amount; a hybridoma producing the monoclonal antibody; a process for production of the monoclonal antibodies using the hybridoma; and an inhibitory agent for inhibition of physiological actions of IL-6 comprising the monoclonal antibodies.Type: GrantFiled: February 3, 1997Date of Patent: February 2, 1999Assignees: Tosoh Corporation, Tadamitsu KishimotoInventors: Tadamitsu Kishimoto, Daisuke Miki, Takashi Saito, Kiyoshi Yasukawa, Hiroshi Suzuki
-
Patent number: 5858361Abstract: Disclosed is an anti-idiotypic antibody which reacts with an anti-CA125 antibody and competes with CA125 in its binding to said anti-idiotypic antibody are disclosed which have essentially the same binding specificity. Additionally, the invention relates to cell lines, particularly to hybridoma 3D5 (DSM ACC2120), producing said anti-idiotypic antibodies. Also disclosed are pharmaceutical compositions containing said anti-idiotypic antibodies and specific uses of these antibodies.Type: GrantFiled: February 26, 1996Date of Patent: January 12, 1999Inventors: Uwe Wagner, Harald Schlebusch
-
Patent number: 5851524Abstract: The invention relates to 2 human monoclonal antibodies of sub-classes IgG1 and IgG3, against the Rhesus D antigen and to a pharmaceutical composition containing a mixture of the said antibodies, more particularly intended for the prophylaxis of the haemolytic disease of the newborn. The invention also relates to the heterohybridoma cell lines that produce these antibodies, which are filed with the "Deutsche Sammlung von Mikroorganismen und Zellkulturen" under accession numbers DSM AC 2039 and DSM AC 2040.Type: GrantFiled: February 10, 1997Date of Patent: December 22, 1998Assignees: Association pour l'Essor de la Transfusion Sanguine dans la Region du Nord, BIOTEST Pharma GmbHInventors: Roland Beliard, Ulf Bethke, Dominique Bourel, Ahmed Bouzidi, Herve Broly, Peter Byrne, Magali Holuigue, Michael Kloft, Detlef Rohm
-
Patent number: 5849288Abstract: Non-human chimeric mammals are created from a mammal having hematopoietic cells replaced with hematopoietic cells from a hematopoietic deficient mammal donor, and in which xenogeneic hematopoietic cells and/or tissue are engrafted. The chimeric mammal can produce xenogeneic, preferably human, B and/or T cells, and can be used as a source of mammalian, preferably human, monoclonal antibodies and/or T cells.Type: GrantFiled: June 7, 1995Date of Patent: December 15, 1998Assignee: Yeda Research and Development Co. Ltd.Inventor: Yair Reisner
-
Patent number: 5840585Abstract: Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.Type: GrantFiled: September 17, 1996Date of Patent: November 24, 1998Assignees: Baylor College of Medicine, Board of Regents, The University of Texas SystemInventors: L. Scott Rodkey, Marwan A. Yared, Kenneth J. Moise, Jr.
-
Patent number: 5837540Abstract: The subject invention relates to a method for producing antibodies using as an immunogen a composition comprising soluble crosslinked DesAABB fibrin polymers and soluble non-crosslinked DesAABB fibrin polymers. The invention provides a method for producing fibrin-specific antibodies which, for the purposes of the present invention, are defined as antibodies that specifically bind to soluble crosslinked DesAABB fibrin polymers and soluble non-crosslinked DesAABB fibrin polymers, but which do not specifically bind to: (a) fibrinogen, (b) plasmin-derived fibrinogen degradation products, (c) DesAA fibrin monomers, (d) DesAA fibrin polymers, (e) DesAABB fibrin monomers, (f) crosslinked fibrinogen, (g) DesAA fibrin monomer-fibrinogen complex, and (h) plasmin-derived fibrin degradation products.Type: GrantFiled: June 28, 1996Date of Patent: November 17, 1998Assignee: American Biogenic Sciences, Inc.Inventors: Paul E. Gargan, David G. M. Carville, Nada Dimitrijevic
-
Patent number: 5834214Abstract: The invention relates to in vitro detection of human pancreatitis-associated protein (hPAP) for the purpose of screening for cystic fibrosis. hPAP is quantitated in a biological sample, preferably blood, and a high value is indicative of pancreatic dysfunction. Immunoassays as rapid, reliable methods for hPAP quantitation are provided as are antibodies for use in the assays and hybridomas for production of monoclonal antibodies preferred for use in the assays.Type: GrantFiled: August 30, 1995Date of Patent: November 10, 1998Assignee: Institut National de la Sante et de la Recherche MedicaleInventors: Juan-Lucio Iovanna, Jean-Charles Dagorn, Volker Keim, Jacques Sarles
-
Patent number: 5830681Abstract: Monoclonal antibodies and fragments thereof, with binding specificity for an epitope on the carboxy terminus of prothrombin activation peptide F1.2, which can be used in immunoassays to predict thrombosis by measuring the extent of activation of prothrombin. These monoclonal antibodies are also included in a kit for performing such immunoassays.Type: GrantFiled: December 30, 1993Date of Patent: November 3, 1998Assignee: Akzo Nobel N.V.Inventors: Marcie J. Hursting, Bryan T. Butman, Jerald P. Steiner, Bryant M. Moore, Frederick A. Dombrose
-
Patent number: 5821068Abstract: A monoclonal antibody that reacts with a human soluble fibrin but not with a human fibrinogen; a hybridoma that secretes the above antibody; and a method of assaying a human soluble fibrin with the above antibody. It is possible to determine the amount of soluble fibrin in the plasma of a patient specifically, readily and rapidly by agglutination and EIA without being affected by plasma fibrinogen, plasmin-degradation product of fibrinogen, fibrin fragment, and plasmin-degradation product of stabilized fibrin even without pretreating the plasma sample.Type: GrantFiled: September 22, 1995Date of Patent: October 13, 1998Assignee: Iatron Laboratories, Inc.Inventors: Gilbu Soe, Isao Kohno, Kimiko Inuzuka, Yumiko Ito
-
Patent number: 5798213Abstract: The present invention provides monoclonal antibodies against peptides having an amino acid sequence described in Sequence No. 1 or No. 2, the peptides being found in human thymidine phosphorylase and human platelet-derived endothelial cell growth factor. The Invention also provides an immunoassay for human thymidine phosphorylase and/or human platelet-derived endothelial cell growth factor using the monoclonal antibodies. The monoclonal antibodies of the invention recognize human thymidine phosphorylase and human platelet-derived endothelial cell growth factor, and thus are useful in the diagnosis and treatment of various tumors and their metastasis and diseases accompanying abnormal angiogenesis.Type: GrantFiled: August 21, 1996Date of Patent: August 25, 1998Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Kazutaka Miyadera, Yuji Yamada, Yuji Takebayashi, Shinichi Akiyama
-
Patent number: 5786153Abstract: A method for substantially preventing coating of hydrophobic material on a probe of an automated analyzer during an assay is described. An automated analyzer having a probe is provided. A composition comprising a non-denaturing surfactant and a reagent for use in the assay is provided. The probe is contacted with the composition during the assay such that hydrophobic material is substantially prevented from coating the probe on the automated analyzer. Compositions for preventing such probe coating are also described. Methods and compositions comprising a non-denaturing surfactant for enhancing the stability of reagents used in an assay are also described.Type: GrantFiled: September 12, 1996Date of Patent: July 28, 1998Assignee: Chiron Diagnostics CorporationInventors: Wei-Chao Ni, Anna Marie Detert, James Joseph Hughes
-
Patent number: 5747337Abstract: Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: May 5, 1998Assignee: The Scripps Research InstituteInventors: Theodore S. Zimmerman, Carol A. Fulcher
-
Patent number: 5744318Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.Type: GrantFiled: December 30, 1994Date of Patent: April 28, 1998Assignee: Alteon Inc.Inventors: Henry W. Founds, Homayoun Sadeghi
-
Patent number: 5712157Abstract: The present invention relates to monoclonal antibodies and a method for the quantification of apolipoprotein(a) and lipoprotein(a) present in human body fluids. The method is not sensitive to the presence of plasminogen or the apo(a) kringle 4 repeats. The assay involves the addition of the test sample to an immobilized anti-apo(a) antibody and forming a first immobilized complex of apolipoprotein(a)/anti-apo(a) first antibody, contacting first immune complex with an anti-apo(a) monoclonal antibody specific for apo(a) with no crossreactivity to plasminogen and which does not identify the kringle 4 type 2 apo(a) repeats and thereafter quantitating apo(a) based on the amount of bound anti-apo(a) monoclonal antibody. Immobilized goat or rabbit anti-human apo(a) antibody can be employed as the first capture antibody and the mouse anti-apo(a) monoclonal antibody as second antibody. The amount of anti-apo(a) monoclonal antibody bound is quantitated through binding of a third antibody enzyme conjugant, e.g.Type: GrantFiled: December 20, 1994Date of Patent: January 27, 1998Assignee: University of WashingtonInventors: Santica M. Marcovina, John J. Albers
-
Patent number: 5620856Abstract: The invention provides method and kits for detecting a metallic cation in a sample of a body fluid. The preferred method and kits include the use of at least two different types of antibodies having different specificities. In the preferred method, the sample of body fluid can be contacted with an effective amount of a capture antibody specific for a naturally occurring polypeptide that can bind the metallic cation to form a first antigen-antibody complex. An effective amount of an antibody specific for an epitope on a metallic cation-naturally occurring polypeptide complex or an antibody specific for a metallic cation is added to the first antigen-antibody complex to form a second antigen-antibody complex. The amount of the metallic cation in the sample of body fluid is determined by detecting the amount of the second antigen-antibody complex.Type: GrantFiled: June 6, 1995Date of Patent: April 15, 1997Assignee: BioNebraska, Inc.Inventors: Randall R. Carlson, Jay S. Stout, Dwane E. Wylie, Fred W. Wagner, Malcolm Riddell
-
Patent number: 5614394Abstract: A method for making an monoclonal antibody specific for vitamin B12 by immunizing mice with vitamin B12-b-acid and isolating hybridomas that produce monoclonal antibodies which have an affinity constant for B12 greater than 5.times.10.sup.9 l/mol is disclosed.Type: GrantFiled: May 16, 1995Date of Patent: March 25, 1997Assignee: Boehringer Mannheim GmbHInventors: Nicholas R. Hoyle, Gunter Pappert, Michael Grol, Christa Hubner-Parajsz
-
Patent number: 5597726Abstract: The present invention relates to a naturally occurring, minimally modified LDL antigen which is present in human atherosclerotic lesions as well as in the serum of a high percentage of patients with coronary artery disease. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the invention, and methods for using the antibodies in the diagnosis and treatment of atherosclerotic disease.Type: GrantFiled: March 30, 1995Date of Patent: January 28, 1997Assignee: Eli Lilly and CompanyInventors: Thomas F. Bumol, Leslie M. McEvoy